Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Operating Leases: 2019-2025

Historic Operating Leases for Intellia Therapeutics (NTLA) over the last 7 years, with Sep 2025 value amounting to $70.6 million.

  • Intellia Therapeutics' Operating Leases fell 14.38% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.6 million, marking a year-over-year decrease of 14.38%. This contributed to the annual value of $190.0 million for FY2024, which is 96.34% up from last year.
  • Intellia Therapeutics' Operating Leases amounted to $70.6 million in Q3 2025, which was down 6.63% from $75.6 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Operating Leases high stood at $190.0 million for Q4 2024, and its period low was $60.0 million during Q2 2022.
  • Its 3-year average for Operating Leases is $99.3 million, with a median of $92.1 million in 2024.
  • As far as peak fluctuations go, Intellia Therapeutics' Operating Leases spiked by 320.46% in 2021, and later dropped by 18.58% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Operating Leases (Quarterly) stood at $64.9 million in 2021, then skyrocketed by 75.65% to $114.0 million in 2022, then dropped by 15.15% to $96.7 million in 2023, then spiked by 96.34% to $190.0 million in 2024, then declined by 14.38% to $70.6 million in 2025.
  • Its Operating Leases stands at $70.6 million for Q3 2025, versus $75.6 million for Q2 2025 and $80.5 million for Q1 2025.